LLY — ELI LILLY AND COMPANY

Eli Lilly makes the world's most effective approved anti-obesity drug, has treated less than 3% of the eligible patient population in its largest market, and has beaten every clinical challenger to date. At $936 and a market capitalization approaching $1 trillion, the growth story is not in doubt — it is priced in. The business deserves admiration; the stock, at these prices, does not demand ownership.

---

The pharmaceutical industry in early 2026 is sorting itself into two eras: the one before GLP-1 receptor agonists transformed the treatment of obesity and metabolic disease, and the one after. Revenues in the category that barely existed five years ago now approach $60 billion annually, growing at rates that no other drug class in history has matched at this scale. The consensus has long since caught up. Novo Nordisk and Eli Lilly dominate analyst reports, financial media, and investor conference agendas with an intensity that would have seemed implausible when Ozempic was still a niche diabetes maintenance therapy. The question that consensus has not yet answered cleanly is whether the dominant company in the dominant drug class of the decade is, at the current price, a vehicle for wealth creation or a vehicle for paying full retail for someone else's insight.

The broader pharmaceutical backdrop makes the GLP-1 story more complicated than the simple penetration argument implies. Drug pricing in the United States in 2026 is politically contested in a way it has not been since the early 2000s. The Trump administration negotiated direct Medicare and Medicaid pricing deals with Lilly and Novo Nordisk in late 2025, bringing the government price for tirzepatide to $245 per month — roughly 75% below the list price. The formal IRA negotiation timeline means tirzepatide will not face the most aggressive form of statutory price negotiation until the end of the decade, but the political pricing pressure has arrived ahead of schedule. Most-Favored-Nation pricing legislation remains contested, with CEO David Ricks actively opposing its codification into law even while signing the executive-level deals it implies. A company in this position — signing pricing agreements under political pressure while simultaneously lobbying against their permanence — is not in a comfortable operating environment. The pricing trajectory matters enormously for the investment case, and it is not yet stable.

The anti-obesity drug market is structurally unusual in pharmaceutical history: an enormous addressable population, a genuinely novel efficacy profile, and a near-complete absence of prior approved therapy. Roughly 42% of American adults — approximately 100 million people — meet clinical criteria for obesity treatment. As of late 2024, fewer than 3 million were receiving a GLP-1 medication, representing under 3% penetration of the eligible pool. Goldman Sachs projects approximately 15 million US patients on anti-obesity medications by 2030, implying a fivefold expansion in the treated population even under a relatively conservative scenario. The global market, estimated at $47 to $53 billion in 2024, is projected to reach $100 to $157 billion by 2030 at a compound annual growth rate in the range of 17%. These are not speculative figures — they are anchored in revenues that already exist and a penetration rate that is, by any historical standard, embryonic.

The industry has a two-horse structure that is unlikely to change dramatically before 2028. Eli Lilly and Novo Nordisk together controlled over 95% of the GLP-1 market through 2024 and into 2025. Novo's Ozempic ($17.5 billion in 2024 revenue) and Wegovy ($8.4 billion) established the category; Lilly's Mounjaro ($23 billion in 2025 alone) and Zepbound ($13.5 billion) are overtaking it. Manufacturing capacity is the practical barrier to new entry — biologics manufacturing for injectable peptides is capital-intensive, time-consuming, and subject to FDA oversight at every step. Large pharmaceutical companies — Pfizer paid $10 billion for Metsera, Roche paid $2.7 billion for Carmot — are buying their way into the race rather than building from scratch, which underscores how durable the incumbent manufacturing position appears to those trying to replicate it.

Eli Lilly is, at its core, a branded pharmaceutical company that develops, manufactures, and markets prescription drugs. It operates across cardiometabolic health (65% of 2025 revenue), oncology (19%), immunology (10%), and neuroscience (3%). In 2025, the company generated $65.2 billion in total revenue, up 45% from $45 billion in 2024 and more than double the $28 billion it recorded three years earlier. The engine of this growth is a single molecule: tirzepatide, marketed as Mounjaro for Type 2 diabetes and Zepbound for obesity. Combined, Mounjaro and Zepbound generated $36.5 billion in 2025 revenue — 56% of total company sales — making tirzepatide the best-selling drug in the world by a meaningful margin. Everything else at Lilly, including Verzenio ($5.7 billion in oncology), Jardiance, Taltz, and Kisunla (the newly approved Alzheimer's therapy), exists in the shadow of this single franchise.

The tirzepatide moat is clinical before it is commercial, and the clinical evidence is specific enough to examine directly. Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic peptide) receptor simultaneously. Semaglutide, the active molecule in Ozempic and Wegovy, activates only GLP-1. In the SURMOUNT-5 Phase 3 trial, published in the New England Journal of Medicine, patients taking tirzepatide at the maximum dose lost an average of 20.2% of body weight at 72 weeks. Patients on semaglutide lost 13.7% — a 6.5 percentage point gap that is not a rounding error in a field where 5% additional weight loss can mean the difference between clinical meaningfulness and a formulary negotiation win. When Novo Nordisk's most advanced next-generation candidate, CagriSema (a GLP-1/amylin dual agonist), was tested head-to-head against Zepbound in 2025, Zepbound won again: 23.6% versus 20.2% weight loss. Novo's best new drug could not beat Lilly's existing approved product.

Drug	Company	Mechanism	Weight Loss (% body weight)	Core Patent Expiry
Zepbound / Mounjaro (tirzepatide)	Eli Lilly	GLP-1 + GIP dual agonist	20.2% (vs. Wegovy); 23.6% (vs. CagriSema)	~2036
Wegovy / Ozempic (semaglutide)	Novo Nordisk	GLP-1 mono-agonist	13.7% (vs. Zepbound)	~2031–2033
CagriSema (cagrilintide + semaglutide)	Novo Nordisk	GLP-1 + amylin dual	20.2% (vs. Zepbound 23.6%)	In development
Retatrutide	Eli Lilly	GLP-1 + GIP + glucagon triple agonist	Phase 3 (early data: ~24%+)	Pipeline

The competitive position is strengthening, not eroding. Tirzepatide's core patent runs to approximately 2036 — three to five years longer than semaglutide's primary protection — which means generics cannot enter the obesity market on tirzepatide until the mid-2030s at the earliest. Novo Nordisk's oral semaglutide reached FDA approval before Lilly's oral candidate orforglipron, but the efficacy comparison is not in Novo's favor: oral semaglutide demonstrated approximately 16.6% weight loss in clinical trials, while orforglipron showed 12.4%. Novo was first to market with an oral GLP-1, but the most effective oral product will likely be Lilly's. The pattern is consistent: Novo moves first, Lilly moves better.

The financial profile of the business reflects both its exceptional economics and the extraordinary capital demands of the current moment. Full-year 2025 revenue was $65.2 billion. Gross margin was approximately 83%, a function of the dominant contribution from branded pharmaceuticals sold at premium pricing. Operating cash flow in the trailing twelve months was $16.8 billion. But free cash flow — the number that matters to the patient investor — was only $9 billion, depressed by capital expenditures of $7.8 billion. Lilly has committed over $50 billion to manufacturing expansion since 2020, including $27 billion announced in February 2025 alone, representing the most ambitious manufacturing buildout in the company's 148-year history. The debt load has grown to match: long-term debt reached $28.5 billion at year-end 2024, up from $18.3 billion a year earlier. This is a deliberate strategic choice — management is borrowing to build capacity for a product that is already demand-constrained — and it is arguably the right choice. But it means the balance sheet currently carries over $30 billion in net debt while the FCF statement understates normalized earnings power by several billion dollars annually.

GAAP and non-GAAP figures diverge materially at Lilly and the divergence deserves attention. GAAP diluted EPS for 2025 was approximately $21.75; the 2026 non-GAAP guidance midpoint is $34.25 — a difference of roughly $12.50 per share. The reconciling items include stock-based compensation (a real economic cost, ongoing and recurring), amortization of acquired intangibles (a real cost incurred when acquiring companies, deferred into the income statement), and acquired in-process research and development charges — Lilly absorbed $1.57 billion in Q1 2025 alone on the Scorpion Therapeutics oncology deal, taken immediately to the income statement under GAAP. These are not fictitious charges. The investor who relies on non-GAAP EPS as the primary valuation denominator is effectively agreeing to ignore the cost of stock compensation paid to management and the real economic cost of acquiring the pipeline. Neither is costless.

David Ricks has served as Chairman, President, and CEO since January 2017. Under his tenure, revenue grew from approximately $21 billion to $65 billion, and the company crossed a $1 trillion market capitalization in 2024. The five-year total shareholder return through late 2024 was approximately 571%. His capital allocation record is coherent: R&D spending grew from $9.3 billion in 2023 to $11 billion in 2024, against an industry trend where most large pharmaceutical peers cut research budgets. The $15 billion share repurchase program authorized in late 2024 sounds large, but actual buyback execution has been modest — approximately $2.5 billion in 2024 — as the manufacturing buildout absorbs available capital. The share count has declined fractionally. This is a management team betting comprehensively on the GLP-1 opportunity: building capacity, buying pipeline, and paying scientists, with capital return to shareholders as a secondary priority. That bet has been correct so far. Whether it remains correct depends on how pricing pressure evolves over the next three to five years.

The quarterly trajectory of the incretin franchise — Mounjaro and Zepbound together — is the single most important evidence in this analysis. It shows a business not approaching any visible ceiling.

Period	Mounjaro Revenue	Zepbound Revenue	Total Incretin	International Mounjaro
Q1 2024	$1.8B	$0.5B	$2.3B	—
Q2 2024	~$3.1B	~$1.2B	~$4.3B	—
Q3 2024	~$3.1B	~$1.3B	~$4.4B	—
Q4 2024	$3.5B	$1.9B	$5.4B	~$0.9B
Q1 2025	$3.8B	$2.3B	$6.1B	—
Q4 2025	$7.4B	$4.2B	$11.6B	$3.3B
FY 2024	$11.5B	$4.9B	$16.4B	—
FY 2025	$23.0B	$13.5B	$36.5B	—

Total quarterly incretin revenue grew from $2.3 billion in Q1 2024 to $11.6 billion in Q4 2025 — a fivefold increase in seven quarters. International Mounjaro revenue grew from approximately $899 million in Q4 2024 to $3.3 billion in Q4 2025, a 267% increase in a single year, driven almost entirely by volume as Lilly moves the molecule into markets where the majority of the world's obese population lives. Lilly has captured approximately 3 million US patients out of 100 million clinically eligible — less than 3% of the addressable domestic population. Goldman Sachs projects approximately 15 million US patients on anti-obesity medications by 2030. If Lilly retains half the treated market at that point, and average pricing settles near $6,000 annually per patient (roughly half of current levels, reflecting continued pricing compression), US Zepbound revenue alone would approach $45 billion by 2030. Add the international opportunity, the diabetes indication, and the pipeline, and the theoretical ceiling on this franchise is genuinely enormous.

The practical question is not whether the ceiling is high. It is whether the investor at $936 is paying for the ceiling or the floor. The answer, on any rigorous earnings-based measure, is that the investor is paying for the ceiling. At a stock price of $936 and a market capitalization of approximately $981 billion, the trailing GAAP price-to-earnings ratio is approximately 43 times. On a pre-tax basis — which strips out differences in tax rates between companies and is the more economically precise comparison — the ratio is approximately 35 times trailing earnings. The 2026 non-GAAP guidance midpoint of $34.25 per share implies a forward price-to-earnings ratio of approximately 27 times. But non-GAAP earnings exclude stock compensation and acquisition charges that are real, recurring economic costs of running this business; using those numbers flatters the multiple. The free cash flow yield at $9 billion against a $981 billion market cap is approximately 0.9% — an asset-quality figure that is extraordinary, but a return figure that is not. Even adjusting for the capex cycle, the earnings yield available to the buyer at $936 is not consistent with the 10 to 12% long-term returns that have historically defined excellent investment outcomes.

The most intelligent bear on this stock frames the argument not as a criticism of the business but as a timing observation: pricing compression will arrive faster than volume growth can absorb it. The 2026 guidance already embeds a "low to mid-teens" pricing headwind — roughly 12 to 15 percentage points of drag — requiring volume to grow 35 to 40% just to deliver 25% revenue growth. That is achievable for now, given the early penetration numbers, but the pricing denominator is declining in real terms every quarter as government and PBM contracts reset. Real-world data from Novo Nordisk showed semaglutide outperforming tirzepatide on cardiovascular outcomes in one observational study, giving payers a data-driven argument for preferring the cheaper molecule on a formulary. The $245/month Medicare deal is a floor; MFN legislation, if codified, could make it a ceiling applicable across payer categories. The bear is not saying the volume growth fails — the bear is saying that volume must run faster and faster each year just to stay in place on revenue, and eventually it cannot.

The answer to the bear is that the volume growth has, in fact, accelerated: Q4 2025 volume grew 46% even as realized prices declined 5%. Tirzepatide's clinical superiority gives it formulary leverage that semaglutide lacks — payers who try to exclude it face physician pushback from a prescriber community that has seen the SURMOUNT-5 data. Retatrutide, the triple agonist in Phase 3, showed early efficacy data suggesting approximately 24% weight loss — potentially superior to tirzepatide itself — which would reset the clinical bar again and extend patent-protected market leadership past 2040. The argument holds, but it requires a future that must materialize, not one that has already been demonstrated. The distinction matters at $936.

To alter the conclusion, either the price must come down meaningfully or the evidence on pricing compression must become more favorable than the current trajectory implies. At approximately $400, the stock would trade at 15 times normalized pre-tax earnings — the threshold at which the investor stops paying for growth that has not yet occurred. At approximately $600, the valuation begins to reflect a realistic range of outcomes rather than an optimistic one. At $936, the investor owns a business that will almost certainly be larger and more profitable in five years, but pays a price that leaves no compensation for risk.

The business is exceptional. The molecule is the best in the class. The management has executed with rare discipline. The market is enormous, the penetration is early, and the pipeline is pointed in the right direction. At $936, none of that is a secret, and none of it is cheap.